BlackRock
DTIL icon

BlackRock’s Precision BioSciences DTIL Stock Holding History

BlackRock’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Buy
199,761
+31,430
+19% +$145K ﹤0.01% 4310
2025
Q4 		$700K Buy
168,331
+69,632
+71% +$395K ﹤0.01% 4403
2025
Q3 		$545K Buy
98,699
+41,209
+72% +$197K ﹤0.01% 4438
2025
Q2 		$241K Buy
57,490
+2,671
+5% +$13.2K ﹤0.01% 4621
2025
Q1 		$261K Sell
54,819
-303
-0.5% -$1.54K ﹤0.01% 4552
2024
Q4 		$210K Buy
55,122
+9
+0% +$66 ﹤0.01% 4610
2024
Q3 		$494K Buy
55,113
+2,265
+4% +$21.8K ﹤0.01% 4334
2024
Q2 		$514K Buy
52,848
+26,446
+100% +$312K ﹤0.01% 4337
2024
Q1 		$358K Sell
26,402
-10,897
-29% -$133K ﹤0.01% 4462
2023
Q4 		$408K Hold
37,299
– – ﹤0.01% 4473
2023
Q3 		$382K Sell
37,299
-3,192
-8% -$49.1K ﹤0.01% 4491
2023
Q2 		$639K Sell
40,491
-9,007
-18% -$206K ﹤0.01% 4422
2023
Q1 		$1.12M Sell
49,498
-5,603
-10% -$185K ﹤0.01% 4301
2022
Q4 		$1.97M Sell
55,101
-22,107
-29% -$874K ﹤0.01% 4145
2022
Q3 		$3.01M Sell
77,208
-2,211
-3% -$105K ﹤0.01% 3985
2022
Q2 		$3.81M Sell
79,419
-72,804
-48% -$4.27M ﹤0.01% 3946
2022
Q1 		$14.1M Buy
152,223
+5,839
+4% +$793K ﹤0.01% 3391
2021
Q4 		$32.5M Buy
146,384
+6,929
+5% +$1.94M ﹤0.01% 2968
2021
Q3 		$48.3M Buy
139,455
+9,136
+7% +$3.1M ﹤0.01% 2682
2021
Q2 		$48.9M Sell
130,319
-9,884
-7% -$2.97M ﹤0.01% 2719
2021
Q1 		$43.5M Buy
140,203
+6,166
+5% +$2.16M ﹤0.01% 2707
2020
Q4 		$33.5M Buy
134,037
+8,917
+7% +$2.19M ﹤0.01% 2720
2020
Q3 		$23.1M Buy
125,120
+20,040
+19% +$3.99M ﹤0.01% 2779
2020
Q2 		$26.3M Buy
105,080
+24,003
+30% +$5.26M ﹤0.01% 2656
2020
Q1 		$14.7M Sell
81,077
-8,371
-9% -$2.19M ﹤0.01% 2778
2019
Q4 		$37.3M Buy
89,448
+65,305
+270% +$20.5M ﹤0.01% 2541
2019
Q3 		$6.08M Buy
24,143
+2,974
+14% +$968K ﹤0.01% 3423
2019
Q2 		$8.41M Buy
21,169
+17,709
+512% +$7.13M ﹤0.01% 3329
2019
Q1 		$1.86M Buy
+3,460
New +$1.84M ﹤0.01% 3732

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock's DTIL Position: Q1 2026 in Review

BlackRock increased its Precision BioSciences (DTIL) stake by 19% in Q1 2026, buying an estimated $145K and bringing the position to 199,761 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #4310.

BlackRock first reported a position in DTIL in Q1 2019 and has held it in 29 quarters since. The position peaked at $48.9M in Q2 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • BlackRock held 199,761 shares of Precision BioSciences worth $1.1M as of Q1 2026.
  • BlackRock bought 31,430 Precision BioSciences shares in Q1 2026, an estimated $145K.
  • Precision BioSciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4310 holding.
  • BlackRock first reported a position in Precision BioSciences in Q1 2019 and has held it in 29 quarters since.
  • BlackRock's Precision BioSciences position peaked at $48.9M in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.